Zobrazeno 1 - 10 of 81 pro vyhledávání: '"Kevin Quackenbush"'
3
Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma
Autor: John J. Arcaroli, Ying Chen, Vasilis Vasiliou, Surendra Singh, Stacey M. Bagby, David C. Thompson, David J. Orlicky, Wells A. Messersmith, Alicia Purkey, Kevin Quackenbush
Publikováno v: Pancreas. 45:117-122
ObjectivesThe aim of the current study was to examine expression and the role, if any, of aldehyde dehydrogenase (ALDH)1B1 in pancreatic adenocarcinoma.MethodsA tissue microarray of 61 pancreatic cancer patients were evaluated for protein expression
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c46e5312f721760fef323d11195a927
https://doi.org/10.1097/mpa.0000000000000542
Zobrazit plný text záznamu
4
Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models
Autor: Kevin Quackenbush, John J. Arcaroli, Stacey M. Bagby, Joe L. Guy, Anna R Schreiber, Betelehem W. Yacob, Thomas Crowell, Thea Kalebic, Hadi Danaee, Wells A. Messersmith, Todd M. Pitts, Bradley Stringer, Anna Nguyen
Background Antibody-drug conjugates (ADCs) are an emerging technology consisting of an antibody, linker, and toxic agent, which have the potential to offer a targeted therapeutic approach. A novel target recently explored for the treatment of pancrea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946602646f76f80a335f8b08e9935437
https://europepmc.org/articles/PMC6324574/
Zobrazit plný text záznamu
6
Abstract B050: Evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models
Autor: John J. Arcaroli, Todd M. Pitts, Joe L. Guy, Stacey M. Bagby, Anna R Schreiber, Bradley Stringer, Anna Nguyen, Thea Kalebic, Thomas Crowell, Kevin Quackenbush, Wells A. Messersmith, Betelehem W. Yacob, Hadi Danaee
Publikováno v: Molecular Cancer Therapeutics. 17:B050-B050
Background: Antibody-drug conjugates (ADCs) are an emerging technology consisting of antibody, linker, and toxic agent, which have the potential to offer a more targeted therapeutic approach than standard chemotherapy regimens. ADCs selectively bind
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97a452634d968b2e1c6ab3e7ea7abd46
https://doi.org/10.1158/1535-7163.targ-17-b050
Zobrazit plný text záznamu
7
Regression of a Fungating Tumor After Hypofractionated Radiation Therapy in a Patient With Metastatic Breast Cancer
Autor: Arya Amini, Christine M. Fisher, Rachel Rabinovitch, Kevin Quackenbush
Publikováno v: Cureus
Radiation therapy is a well-established palliative treatment for symptomatic metastases from breast cancer. This is also true of symptomatic primary breast tumors in patients with metastatic disease or in those who are medically inoperable. Further,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fa538e9dad12f63461ee7782c910e35
https://doi.org/10.7759/cureus.1417
Zobrazit plný text záznamu
8
Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
Autor: Stacey M. Bagby, Kevin Quackenbush, Eun Kee Song, Alicia Purkey, S. Gail Eckhardt, Benjamin Cross, Todd M. Pitts, Csaba Gajdos, Wells A. Messersmith, Aaron Scott, John J. Arcaroli, Martin D. McCarter, Hubert Fenton, Aik Choon Tan
Publikováno v: PLoS ONE, Vol 12, Iss 11, p e0187173 (2017)
PLoS ONE
Background Dysregulation of the Src pathway has been shown to be important at various stages of cancer. Dasatinib is a potent Src/Abl inhibitor and has demonstrated to have anti-proliferative and anti-invasive activity in many preclinical models. The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318572cb2c4d1ee05a413a09b8a0e4a6
http://europepmc.org/articles/PMC5665512?pdf=render
Zobrazit plný text záznamu
9
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model
Autor: Alicia Purkey, Gail Eckhardt, Robin Kate Kelley, Kevin Quackenbush, Wai Meng David Tai, Eunice L. Kwak, Alan P. Venook, Jeffrey B. Kaplan, Guoliang Wang, John J. Arcaroli, Patrick J. Blatchford, Chloe E. Atreya, David P. Ryan, Wells A. Messersmith, Eun Kee Song, Rachel Yahn, Stacey M. Bagby, Todd M. Pitts, Aik Choon Tan
Publikováno v: International Journal of Cancer. 136:1967-1975
Antiangiogenic therapy is commonly used for the treatment of colorectal cancer (CRC). Although patients derive some clinical benefit, treatment resistance inevitably occurs. The MET signaling pathway has been proposed to be a major contributor of res
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9ce1393c3381736af53f5b09825ebee6
https://doi.org/10.1002/ijc.29225
Zobrazit plný text záznamu
10
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
Autor: John J. Arcaroli, Todd M. Pitts, Alicia Purkey, K. Bikkavilli, W. M. Tai, Michelle Vanscoyk, Stacey M. Bagby, Aik Choon Tan, S. G. Eckhardt, Benjamin Cross, Robert A. Winn, Kelly L. McPhillips, Rebecca W. Powell, Wells A. Messersmith, Eun-Kee Song, Kevin Quackenbush
Publikováno v: British Journal of Cancer
Background: Dysregulation of the Notch pathway has been identified to play an important role in the development and progression of colorectal cancer (CRC). In this study, we used a patient-derived CRC explant model to investigate the efficacy of the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cbc440a16180e09b6a153bc58574055
https://doi.org/10.1038/bjc.2013.361
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje